Review





Similar Products

95
InvivoGen peptide agarose
Peptide Agarose, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+2/pm42204975-55-22-24?v=InvivoGen
Average 95 stars, based on 1 article reviews
peptide agarose - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

95
InvivoGen peptide m
Peptide M, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+2/bio_rxiv__64898__2026__05__25__727697-116-6-8?v=InvivoGen
Average 95 stars, based on 1 article reviews
peptide m - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

86
Takeda insulinotropic polypeptide glp 1 glucagon like peptide 1 gpcr g protein coupled receptor lcn 2 lipocalin 2 lgr5 leucine rich repeat
Insulinotropic Polypeptide Glp 1 Glucagon Like Peptide 1 Gpcr G Protein Coupled Receptor Lcn 2 Lipocalin 2 Lgr5 Leucine Rich Repeat, supplied by Takeda, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+2/pm42167400-272-18-69?v=Takeda
Average 86 stars, based on 1 article reviews
insulinotropic polypeptide glp 1 glucagon like peptide 1 gpcr g protein coupled receptor lcn 2 lipocalin 2 lgr5 leucine rich repeat - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

96
Agilent technologies advancebio peptide map 2 1
Advancebio Peptide Map 2 1, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+2/bio_rxiv__64898__2026__05__12__724256-46-15-26?v=Agilent+technologies
Average 96 stars, based on 1 article reviews
advancebio peptide map 2 1 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

93
Miltenyi Biotec sars cov 2 peptide pools
Comparison of naïve and COVID-19 convalescent donor T cell activation for select AIM pairs. ( a ) Flow cytometry plots comparing naïve and COVD-19 convalescent donor PBMCs with <t>or</t> <t>without</t> <t>SARS-CoV-2</t> peptide pool stimulation . Five CD4 + T cell ( b ) and five CD8 + T cell ( c ) AIM pairs discriminate naïve (circle) and COVID-19 convalescent (square) donors. ( b , c ) Graphs indicate significant differential expression between naïve and COVID-19 convalescent donors, at 5% FDR (*), ns = not significant.
Sars Cov 2 Peptide Pools, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+2/pmc13341749-188-1-5?v=Miltenyi+Biotec
Average 93 stars, based on 1 article reviews
sars cov 2 peptide pools - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
Cytiva Europe peptides
Comparison of naïve and COVID-19 convalescent donor T cell activation for select AIM pairs. ( a ) Flow cytometry plots comparing naïve and COVD-19 convalescent donor PBMCs with <t>or</t> <t>without</t> <t>SARS-CoV-2</t> peptide pool stimulation . Five CD4 + T cell ( b ) and five CD8 + T cell ( c ) AIM pairs discriminate naïve (circle) and COVID-19 convalescent (square) donors. ( b , c ) Graphs indicate significant differential expression between naïve and COVID-19 convalescent donors, at 5% FDR (*), ns = not significant.
Peptides, supplied by Cytiva Europe, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+2/pmc13200099-106-4-13?v=Cytiva+Europe
Average 94 stars, based on 1 article reviews
peptides - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

96
SPT Labtech resource source identifier mosquito lv crystal spt labtech n a multipep 2 peptide synthesizer cem corp
Comparison of naïve and COVID-19 convalescent donor T cell activation for select AIM pairs. ( a ) Flow cytometry plots comparing naïve and COVD-19 convalescent donor PBMCs with <t>or</t> <t>without</t> <t>SARS-CoV-2</t> peptide pool stimulation . Five CD4 + T cell ( b ) and five CD8 + T cell ( c ) AIM pairs discriminate naïve (circle) and COVID-19 convalescent (square) donors. ( b , c ) Graphs indicate significant differential expression between naïve and COVID-19 convalescent donors, at 5% FDR (*), ns = not significant.
Resource Source Identifier Mosquito Lv Crystal Spt Labtech N A Multipep 2 Peptide Synthesizer Cem Corp, supplied by SPT Labtech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+2/pm42049022-966-2-8?v=SPT+Labtech
Average 96 stars, based on 1 article reviews
resource source identifier mosquito lv crystal spt labtech n a multipep 2 peptide synthesizer cem corp - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

86
Equillium Inc eq302 eq102 equillium bnz 2 equillium il15 il 21 inhibiting peptide phase 1
Comparison of naïve and COVID-19 convalescent donor T cell activation for select AIM pairs. ( a ) Flow cytometry plots comparing naïve and COVD-19 convalescent donor PBMCs with <t>or</t> <t>without</t> <t>SARS-CoV-2</t> peptide pool stimulation . Five CD4 + T cell ( b ) and five CD8 + T cell ( c ) AIM pairs discriminate naïve (circle) and COVID-19 convalescent (square) donors. ( b , c ) Graphs indicate significant differential expression between naïve and COVID-19 convalescent donors, at 5% FDR (*), ns = not significant.
Eq302 Eq102 Equillium Bnz 2 Equillium Il15 Il 21 Inhibiting Peptide Phase 1, supplied by Equillium Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+2/pm42033586-94-0-4?v=Equillium+Inc
Average 86 stars, based on 1 article reviews
eq302 eq102 equillium bnz 2 equillium il15 il 21 inhibiting peptide phase 1 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

94
Tocris c78h142n22o20
Comparison of naïve and COVID-19 convalescent donor T cell activation for select AIM pairs. ( a ) Flow cytometry plots comparing naïve and COVD-19 convalescent donor PBMCs with <t>or</t> <t>without</t> <t>SARS-CoV-2</t> peptide pool stimulation . Five CD4 + T cell ( b ) and five CD8 + T cell ( c ) AIM pairs discriminate naïve (circle) and COVID-19 convalescent (square) donors. ( b , c ) Graphs indicate significant differential expression between naïve and COVID-19 convalescent donors, at 5% FDR (*), ns = not significant.
C78h142n22o20, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+2/pm41998398-45-36-42?v=Tocris
Average 94 stars, based on 1 article reviews
c78h142n22o20 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

Image Search Results


Comparison of naïve and COVID-19 convalescent donor T cell activation for select AIM pairs. ( a ) Flow cytometry plots comparing naïve and COVD-19 convalescent donor PBMCs with or without SARS-CoV-2 peptide pool stimulation . Five CD4 + T cell ( b ) and five CD8 + T cell ( c ) AIM pairs discriminate naïve (circle) and COVID-19 convalescent (square) donors. ( b , c ) Graphs indicate significant differential expression between naïve and COVID-19 convalescent donors, at 5% FDR (*), ns = not significant.

Journal: Scientific Reports

Article Title: Prediction of SARS-CoV-2 exposure through T cell activation profiles

doi: 10.1038/s41598-026-48323-7

Figure Lengend Snippet: Comparison of naïve and COVID-19 convalescent donor T cell activation for select AIM pairs. ( a ) Flow cytometry plots comparing naïve and COVD-19 convalescent donor PBMCs with or without SARS-CoV-2 peptide pool stimulation . Five CD4 + T cell ( b ) and five CD8 + T cell ( c ) AIM pairs discriminate naïve (circle) and COVID-19 convalescent (square) donors. ( b , c ) Graphs indicate significant differential expression between naïve and COVID-19 convalescent donors, at 5% FDR (*), ns = not significant.

Article Snippet: Curated SARS-CoV-2 peptide pools (130-127-309, Miltenyi and 3622-1, Mabtech) containing 9-22 mer peptides were used to activate SARS-CoV-2 antigen-responsive CD4 + and CD8 + T cells.

Techniques: Comparison, Activation Assay, Flow Cytometry, Quantitative Proteomics

Comparison of naïve and COVID-19 convalescent donor T cell activation using fold-change and difference analyses. ( a ) Difference analysis for AIM pairs identified from the CD4 + T cell population; wherein, the median background subtracted activation marker pair signal from the naïve donor samples was subtracted from the background subtracted activation AIM pair signals detected from each COVID convalescent donor sample. ( b ) Fold-change analysis for marker pairs identified from the CD4 + T cell population; wherein, the background subtracted activation AIM pair signals detected from each COVID convalescent donor sample were divided by the median background subtracted activation marker pair signal from the naïve donor samples. ( c ) Difference analysis for AIM pairs identified from the CD8 + T cell population, analyzed similarly to the CD4 + T cell population. ( d ) Fold-change analysis for marker pairs identified from the CD8 + T cell population, analyzed similarly to the CD4 + T cell population. Each data point represents cells from a single COVID-19 convalescent donor treated with a single SARS-CoV-2 peptide pool in comparison to the median signal from the naïve donors. For all graphs, each unique symbol color represents data from a unique COVID-19 convalescent donor.

Journal: Scientific Reports

Article Title: Prediction of SARS-CoV-2 exposure through T cell activation profiles

doi: 10.1038/s41598-026-48323-7

Figure Lengend Snippet: Comparison of naïve and COVID-19 convalescent donor T cell activation using fold-change and difference analyses. ( a ) Difference analysis for AIM pairs identified from the CD4 + T cell population; wherein, the median background subtracted activation marker pair signal from the naïve donor samples was subtracted from the background subtracted activation AIM pair signals detected from each COVID convalescent donor sample. ( b ) Fold-change analysis for marker pairs identified from the CD4 + T cell population; wherein, the background subtracted activation AIM pair signals detected from each COVID convalescent donor sample were divided by the median background subtracted activation marker pair signal from the naïve donor samples. ( c ) Difference analysis for AIM pairs identified from the CD8 + T cell population, analyzed similarly to the CD4 + T cell population. ( d ) Fold-change analysis for marker pairs identified from the CD8 + T cell population, analyzed similarly to the CD4 + T cell population. Each data point represents cells from a single COVID-19 convalescent donor treated with a single SARS-CoV-2 peptide pool in comparison to the median signal from the naïve donors. For all graphs, each unique symbol color represents data from a unique COVID-19 convalescent donor.

Article Snippet: Curated SARS-CoV-2 peptide pools (130-127-309, Miltenyi and 3622-1, Mabtech) containing 9-22 mer peptides were used to activate SARS-CoV-2 antigen-responsive CD4 + and CD8 + T cells.

Techniques: Comparison, Activation Assay, Marker

Cytokine production is increased in COVID-19 convalescent donors following stimulation with SARS-CoV-2 peptide pools. ( a ) IFN-γ cytokine production is increased in COVID-19 convalescent donor samples following stimulation with SARS-CoV-2 pp B as monitored via an Enzymatic 2-step ELISpot assay. Shown are a graph and a representative image of ELISpot results. Note: due to a technical issue, pp A failed to elicit an ELISpot response in 2 experiments, even for positive controls, which impacted the naïve to COVID-19 convalescent comparison for the pp A ELISpot data. ( b ) IFN-γ, IL-2, IL-6, and IL-10 cytokine production is increased in COVID-19 convalescent donor samples following SARS-CoV-2 peptide stimulation as monitored via a bead-based flowcytometry assay. ( a, b ) Graphs indicate significant differential expression between naïve and COVID-19 convalescent donors, at 5% FDR (*), ns = not significant. ( c ) Spearman correlation analysis of AIM pairs described in Fig. that significantly discriminated naïve and COVID-19 convalescent samples with cytokine release assay and ELISpot.

Journal: Scientific Reports

Article Title: Prediction of SARS-CoV-2 exposure through T cell activation profiles

doi: 10.1038/s41598-026-48323-7

Figure Lengend Snippet: Cytokine production is increased in COVID-19 convalescent donors following stimulation with SARS-CoV-2 peptide pools. ( a ) IFN-γ cytokine production is increased in COVID-19 convalescent donor samples following stimulation with SARS-CoV-2 pp B as monitored via an Enzymatic 2-step ELISpot assay. Shown are a graph and a representative image of ELISpot results. Note: due to a technical issue, pp A failed to elicit an ELISpot response in 2 experiments, even for positive controls, which impacted the naïve to COVID-19 convalescent comparison for the pp A ELISpot data. ( b ) IFN-γ, IL-2, IL-6, and IL-10 cytokine production is increased in COVID-19 convalescent donor samples following SARS-CoV-2 peptide stimulation as monitored via a bead-based flowcytometry assay. ( a, b ) Graphs indicate significant differential expression between naïve and COVID-19 convalescent donors, at 5% FDR (*), ns = not significant. ( c ) Spearman correlation analysis of AIM pairs described in Fig. that significantly discriminated naïve and COVID-19 convalescent samples with cytokine release assay and ELISpot.

Article Snippet: Curated SARS-CoV-2 peptide pools (130-127-309, Miltenyi and 3622-1, Mabtech) containing 9-22 mer peptides were used to activate SARS-CoV-2 antigen-responsive CD4 + and CD8 + T cells.

Techniques: Enzyme-linked Immunospot, Comparison, Quantitative Proteomics, Release Assay

Unsupervised hierarchical clustering of all 35 CD4 + and CD8 + T cell AIM pair combinations. Using data from normalized samples, unsupervised hierarchical clustering of all 35 CD4 + and CD8 + T cell marker pair combinations separated naïve and COVID-19 convalescent donor samples, except for a single COVID-19 convalescent donor sample stimulated with SARS-CoV-2 pp A (blue arrow). The same donor sample stimulated with SARS-CoV-2 pp B clustered with the COVID-19 convalescent donor samples. Obtaining this clear separation of naïve and convalescent donor samples by chance is very unlikely, p < 2 -10 .

Journal: Scientific Reports

Article Title: Prediction of SARS-CoV-2 exposure through T cell activation profiles

doi: 10.1038/s41598-026-48323-7

Figure Lengend Snippet: Unsupervised hierarchical clustering of all 35 CD4 + and CD8 + T cell AIM pair combinations. Using data from normalized samples, unsupervised hierarchical clustering of all 35 CD4 + and CD8 + T cell marker pair combinations separated naïve and COVID-19 convalescent donor samples, except for a single COVID-19 convalescent donor sample stimulated with SARS-CoV-2 pp A (blue arrow). The same donor sample stimulated with SARS-CoV-2 pp B clustered with the COVID-19 convalescent donor samples. Obtaining this clear separation of naïve and convalescent donor samples by chance is very unlikely, p < 2 -10 .

Article Snippet: Curated SARS-CoV-2 peptide pools (130-127-309, Miltenyi and 3622-1, Mabtech) containing 9-22 mer peptides were used to activate SARS-CoV-2 antigen-responsive CD4 + and CD8 + T cells.

Techniques: Marker